Understanding the Impact of Treatment-Induced Menopause Following Breast Cancer Treatment
MeAgain is an early-stage digital health company based in Co. Dublin, founded by Ana Dinho, a breast cancer survivor. Diagnosed with breast cancer during Covid-19, Ana experienced sudden, severe treatment-induced menopause symptoms when she started Tamoxifen. It took her almost two years to find the right help. That experience is the reason MeAgain exists.
We are building practical, clinically informed support for women experiencing treatment-induced menopause following breast cancer treatment, because too many women are going through this alone and unprepared.
This survey is part of our discovery to understand the real impact of treatment-induced menopause and to ensure what we build genuinely reflects the experiences of the women it is designed for. Your voice matters.
Before you begin, please read:
- All responses are completely anonymous. We do not collect your name, email address, or any information that could identify you.
- No question is mandatory — answer only what you are comfortable with.
- You may stop or close this survey at any time without consequence. No account or login is required.
- Responses are stored securely on the MeAgain website and are accessible only to the MeAgain team. They will not be shared with third parties. Anonymised and aggregated findings may be used to inform MeAgain's product development, communications, and research.
- This is a discovery survey — it does not provide medical advice or diagnosis.
- For full details on how we handle your data please review our Privacy Policy (PDF).
If you are interested in learning more or exploring collaboration, we would love to hear from you — please connect with Ana Dinho on LinkedIn or email: hello@mymeagain.ie
Estimated time: 5–8 minutes